Papula-Nevinpat ESA Business Incubation Centre’s IP partner

12.12.2017

The European Space Agency Business Incubation Centre (ESA BIC) launched its operations in Finland on 30 November 2017. ESA BIC Finland is ESA’s eighteenth business incubation centre, and it’s the second one in the Nordic countries after Sweden.

”Setting up the ESA Business Incubation Centre in Finland is great news for space technology companies. In the coming years, ESA BIC will offer support for new Finnish business ideas based on space technology. We want to make our contribution to help new startups secure their business by encouraging them to pay attention to IP issues right from the start”, says Mr. Markku Simmelvuo, Managing Director, from Papula-Nevinpat.

”It’s important for space technology startups to protect their innovations early on. I’m particularly happy that we have Papula-Nevinpat to advise new companies in IP issues, as they have long experience in working with startups”, says Mr. Kimmo Isbjörnssund, ESA BIC Finland Manager.

During the next five years, ESA BIC Finland will give support to 50 Finnish space technology startups. Finland has strong competence in space technology, such as application-based astronaut training programmes. Finland has participated in ESA programmes since 1987, and has been a Member State since 1995.

Read more about our services for startups.

News

Riikka Palmos and Jussi Mikkola of Papula-Nevinpat have secured their positions in the top tiers by WTR 1000 for 2025

Papula-Nevinpat’s trademark practice has once again been recognized in the top tier of the 2025 edition of the World Trademark Review 1000.

Papula-Nevinpat is thrilled to continue its partnership as the IPR partner for ESA BIC Finland

Papula-Nevinpat is pleased to continue as the ESA BIC Finland program's intellectual property rights (IPR) partner.

Papula-Nevinpat in PTMG’s newsletter: The Evolving Landscape in Ukraine and Russia – Challenges and Strategies for Rights Holders

Riikka Palmos, a European Trademark Attorney, has authored an article discussing key developments in Ukraine and Russia. You can read the article in the latest PTMG (Pharmaceutical Trade Marks Group) newsletter.